- Investing Ideas
- /
- U.S. Biotech Stocks
U.S. Biotech Stocks
Results
437
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
437 companies
Aardvark Therapeutics
Market Cap: US$264.1m
A clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
AARD
US$12.67
7D
12.2%
1Y
n/a
Lyell Immunopharma
Market Cap: US$258.4m
A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
LYEL
US$12.72
7D
0.6%
1Y
-58.2%
Quanterix
Market Cap: US$246.3m
A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
QTRX
US$5.26
7D
-5.7%
1Y
-59.5%
Neurogene
Market Cap: US$246.2m
A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
NGNE
US$17.41
7D
-6.8%
1Y
-55.6%
Atlantic International
Market Cap: US$245.2m
Operates as a staffing company servicing the commercial, professional, finance, direct placement, and managed service provider verticals.
ATLN
US$3.60
7D
-0.6%
1Y
-40.0%
Perspective Therapeutics
Market Cap: US$242.1m
Develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
CATX
US$3.19
7D
-3.0%
1Y
-74.0%
Invivyd
Market Cap: US$237.8m
A biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
IVVD
US$1.14
7D
-8.8%
1Y
9.6%
Puma Biotechnology
Market Cap: US$237.7m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$4.70
7D
4.0%
1Y
83.6%
Vor Biopharma
Market Cap: US$237.3m
Operates as a clinical-stage cell and genome engineering company.
VOR
US$33.81
7D
11.2%
1Y
130.0%
Exagen
Market Cap: US$237.2m
Designs, develops, and commercializes various testing products under the AVISE brand in the United States.
XGN
US$10.57
7D
9.5%
1Y
236.6%
Sagimet Biosciences
Market Cap: US$236.8m
A clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
SGMT
US$7.14
7D
5.8%
1Y
153.2%
Atea Pharmaceuticals
Market Cap: US$230.1m
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
AVIR
US$2.91
7D
-2.0%
1Y
-15.4%
OmniAb
Market Cap: US$227.4m
A biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.
OABI
US$1.56
7D
-6.0%
1Y
-63.1%
Cabaletta Bio
Market Cap: US$225.9m
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
CABA
US$2.31
7D
6.0%
1Y
-42.1%
Ironwood Pharmaceuticals
Market Cap: US$222.5m
A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
IRWD
US$1.27
7D
-13.0%
1Y
-68.7%
Tiziana Life Sciences
Market Cap: US$219.6m
A biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States.
TLSA
US$2.07
7D
16.3%
1Y
99.0%
MDxHealth
Market Cap: US$216.8m
A commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
MDXH
US$4.30
7D
10.3%
1Y
115.0%
Tonix Pharmaceuticals Holding
Market Cap: US$216.5m
A biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease.
TNXP
US$24.00
7D
-15.4%
1Y
75.7%
Ventyx Biosciences
Market Cap: US$196.1m
A clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases.
VTYX
US$2.69
7D
12.6%
1Y
14.0%
Milestone Pharmaceuticals
Market Cap: US$189.9m
A biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
MIST
US$1.97
7D
1.0%
1Y
30.5%
Journey Medical
Market Cap: US$189.4m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$6.90
7D
-5.1%
1Y
26.1%
Coherus Oncology
Market Cap: US$183.6m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.45
7D
-5.2%
1Y
36.8%
Entrada Therapeutics
Market Cap: US$183.1m
A clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
TRDA
US$5.58
7D
0.5%
1Y
-64.6%
Black Diamond Therapeutics
Market Cap: US$177.1m
A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.
BDTX
US$3.11
7D
-5.2%
1Y
-26.5%
MaxCyte
Market Cap: US$177.0m
A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
MXCT
US$1.53
7D
-5.6%
1Y
-60.7%
Sangamo Therapeutics
Market Cap: US$170.4m
A clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
SGMO
US$0.63
7D
15.1%
1Y
-25.0%
Enanta Pharmaceuticals
Market Cap: US$167.0m
A biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
ENTA
US$7.75
7D
-1.1%
1Y
-26.0%
Genelux
Market Cap: US$163.2m
A clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
GNLX
US$4.21
7D
5.0%
1Y
99.5%
Actuate Therapeutics
Market Cap: US$160.9m
A clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
ACTU
US$6.65
7D
-3.1%
1Y
9.6%
AVITA Medical
Market Cap: US$160.1m
Operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
RCEL
US$5.33
7D
-3.8%
1Y
-49.6%
Cassava Sciences
Market Cap: US$157.5m
A clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
SAVA
US$3.10
7D
35.4%
1Y
-90.3%
Protara Therapeutics
Market Cap: US$157.4m
A clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
TARA
US$4.29
7D
33.6%
1Y
134.4%
Achieve Life Sciences
Market Cap: US$157.4m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$2.97
7D
3.5%
1Y
-33.1%
Scilex Holding
Market Cap: US$157.2m
Focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
SCLX
US$28.87
7D
12.5%
1Y
-8.4%
Avalo Therapeutics
Market Cap: US$152.6m
A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.
AVTX
US$11.55
7D
-2.8%
1Y
23.5%
Cybin
Market Cap: US$152.2m
A clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
CYBN
US$5.86
7D
-2.3%
1Y
-40.7%